See you at The Philippine Psychiatric Association Convention for the preview of BrainsWay Deep TMS.
Clinical trials with Deep TMS have not demonstrated the presence of systemic side effects. Some subjects have reported experiencing headaches, application site pain or discomfort and other non-systemic side effects. There is also a very rare risk of seizure associated with the treatment. Subjects with metal in or around the head, such as in metal plates, implants and stents, should not undergo Deep TMS.
BrainsWay Deep TMS is indicated b the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. K1222888. Brainsway is also certified by the CE for the following indications: Major Depression, Bipolar Depression, Schizophrenia- Negative Symptoms, Parkinson’s Disease (with antiparkinsonian medications) , Post-Traumatic Stress Dsorder (PTSD), Smoking Cessation, Autism and Asperger’s Disorder, Alzheimer’s Disease, Chronic Diabetic Pain, Obsessive Compulsive Disorder (OCD), Multiple Sclerosis (MS), Stroke Certification No. 6106GB410141202